Quest Diagnostics Incorporated (DGX) Stock

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated is led by CEO James E. Davis, employs 57,000 people, headquartered in Secaucus, US, publicly traded since 1996.

Quest Diagnostics Incorporated (DGX) stock trades at $230.81 with a market capitalization of $25.48B. The stock is valued at a price-to-earnings (P/E) ratio of 24.45, price-to-book of 3.41, price-to-sales of 2.23. Over the past 52 weeks the stock has ranged between $171.18 and $248.84, and currently trades 7.2% below its 52-week high. It pays a dividend yielding 1.47%.

On profitability, Quest Diagnostics Incorporated generates a return on equity (ROE) of 14.49%, above the typical market average, return on capital employed of 10.79%, an operating margin of 14.53%, a net profit margin of 9.19%.

In its most recent fiscal year, Quest Diagnostics Incorporated reported annual revenue of $11.0B, net profit of $992.0M, revenue has compounded at 3.2% a year over the last five years, profit at -7.1% a year.

The balance sheet shows a debt-to-equity ratio of 0.85, a current ratio of 1.04, total assets of $16.2B, $420.0M in cash and equivalents.

DGX has a beta of 0.55 (less volatile than the overall market).